Overview

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Observational studies suggest that bariatric surgery is the most effective intervention for weight loss. Comparative effectiveness of Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) demonstrate that RYGB is significantly superior to SG in terms of weight loss and glycemic control. Both RYGB and SG increase GLP-1 concentrations which directly affect B-cell function. Data has shown that the postprandial rise in GLP-1 might affect feeding behavior after RYGB and to a lesser extent SG, where the increase in GLP-1 is less marked. In this study the investigators propose to randomize subjects undergoing SG to receive either placebo or Liraglutide, a GLP-1 receptor agonist, to compare weight loss and CV risk factors.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Novo Nordisk A/S
Treatments:
Liraglutide